These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38720801)

  • 21. Preoperative transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients undergoing conversional hepatectomy: a propensity-score matching analysis.
    Liu Y; Zhou B; Tang W; Xu D; Yan Z; Ren L; Zhu D; He G; Wei Y; Chang W; Xu J
    Eur Radiol; 2023 Feb; 33(2):1022-1030. PubMed ID: 36066736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases.
    Zhao G; Liu S; Zhang Y; Zhao T; Wang R; Bian J; Wu J; Zhou J
    Ir J Med Sci; 2022 Jun; 191(3):1139-1145. PubMed ID: 34264426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.
    Chiu SH; Chang PY; Shih YL; Huang WY; Ko KH; Chang WC; Huang GS
    Drug Des Devel Ther; 2020; 14():5029-5041. PubMed ID: 33235441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial.
    Zhou TY; Tao GF; Zhou GH; Zhang YL; Zhu TY; Chen SQ; Wang HL; Wang BQ; Jing L; Chen F
    Int J Surg; 2024 Sep; 110(9):5527-5537. PubMed ID: 38775550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Tang J; Huang Z; Xu J; Lv Q; Wang P
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis.
    Schindler P; Kaldewey D; Rennebaum F; Trebicka J; Pascher A; Wildgruber M; Köhler M; Masthoff M
    J Cancer Res Clin Oncol; 2024 May; 150(5):235. PubMed ID: 38710956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients.
    Sun T; Zhang W; Chen L; Ren Y; Liu Y; Zheng C
    J Cancer; 2022; 13(4):1282-1288. PubMed ID: 35281867
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
    Yang XG; Sun YY; Li DS; Xu GH; Huang XQ
    Front Immunol; 2022; 13():940009. PubMed ID: 35874708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres
    Duan X; Liu J; Han X; Ren J; Li H; Li F; Ju S
    Front Oncol; 2021; 11():793581. PubMed ID: 35127501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
    Bi Y; Ren K; Ren J; Ma J; Han X
    Front Pharmacol; 2022; 13():923585. PubMed ID: 36034827
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug-Eluting Bead Transarterial Chemoembolization Versus Radiofrequency Ablation as an Initial Treatment of Single Small (≤ 3 cm) Hepatocellular Carcinoma.
    Lee S; Jeong YY; Lee BC; Shin SS; Heo SH; Kim HO; Park C; Jeong WG
    J Korean Med Sci; 2023 Oct; 38(42):e362. PubMed ID: 37904659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 μm Drug-Eluting Bead Transcatheter Arterial Chemoembolization.
    Wholey M; Palacios Iii R; Wholey D; Mendez A
    Cureus; 2022 Apr; 14(4):e24047. PubMed ID: 35573558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
    Zhu D; Yuan D; Wang Z; Chen S
    Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
    Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
    Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
    Wu SJ; Ruan DD; Wu QY; Tang Y; Zhang JH; Cai SL; Zhou YF; Luo JW; Fang ZT
    J Hepatocell Carcinoma; 2023; 10():807-820. PubMed ID: 37292114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
    Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
    Bi Y; Shi X; Ren J; Yi M; Han X
    Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.